Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04680637 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT04680637 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 168 participants.
The verdict
NCT04680637, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.
Interventions
- DRUG Placebo
- OTHER Standard of Care
- DRUG Efavaleukin Alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2021-05-06 |
| Est. Completion | 2023-05-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04680637
The ClinicalTrials.gov registry entry for NCT04680637 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04680637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04680637 about?
NCT04680637 is a clinical study titled "Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus". The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.
What is the current status of trial NCT04680637?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2021-05-06. Estimated completion is 2023-05-22.
What interventions are being tested in trial NCT04680637?
The interventions under investigation include: Placebo (DRUG), Standard of Care (OTHER), Efavaleukin Alfa (DRUG).
Who is sponsoring clinical trial NCT04680637?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.